Search for a trial

The effect of transcranial direct current stimulation on processing speed in patients after ischemic stroke

To evaluate the effects of tDCS on information processing speed in comparison to sham tDCS in patients after stroke with ascertained reduced processing speed. A proof of principle study.

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation

2.1 Primary Objectives• Evaluate the safety and tolerability of 2 fixed doses of FRM-0334 (300 and 500 mg daily in 2 sequential periods) over 28 days in subjects with prodromal to moderate FTD-GRN• Assess the PD effects of FRM-0334 on the change…

The effect of explantation of silicone breast implants on neuroimages of the brain in ASIA-syndrome patients: a pilot fMRI-study

To investigate the effect of explantation of silicone breast implants on neuroimaging of the brain (fMRI) in ASIA syndrome patients to gain more insight in the neurophysiological basis and nociceptive system of ASIA syndrome due to SIIS and the…

Synaptic density and tau pathology in Alzheimer's disease

This study has been transitioned to CTIS with ID 2024-517636-22-00 check the CTIS register for the current data. The main objective of the present study is to investigate the association between in vivo regional synaptic loss ([18F]SynVesT-1 PET),…

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel
Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Mild to Moderate Alzheimer*s Disease

This study has been transitioned to CTIS with ID 2024-511610-20-00 check the CTIS register for the current data. Cognitive and functional abilities will be evaluated using psychometric scales (ie, cognitive subscale of the Alzheimer*s Disease…

Imaging inflammation in Alzheimer*s Disease

The main objective is to quantify neuroinflammation using [11C]SMW139 PET-scans in subjects along the AD continuum and age/sex-matched cognitively unimpaired subjects.

A randomized, double-blind, placebo-controlled, parallel-group, phase 2 study to evaluate the safety and efficacy of CT1812 in subjects with mild to moderate Alzheimer's disease

The purpose of this study is to evaluate the safety and efficacy of two doses of the study drug CT1812 per day for six months in subjects with mild to moderate Alzheimer's disease. CT1812 will be compared with a placebo. A placebo is a product…

A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer*s disease

Primary objectives: * To demonstrate the effects of CAD106 and CNP520, respectively, vs. placebo on Time-to-event (TTE), with event defined as a diagnosis of MCI due to AD or dementia due to AD, whichever occurs first during the course of the study…